NEWS

June 29, 2021
Neurogene Announces EMA Grants Orphan Drug Designation to CLN5 Batten Disease Gene Therapy
Learn More
May 11, 2021
Neurogene’s AAV Biodistribution Study Shows Route of Administration Essential Component in Optimizing Gene Therapy Treatment for Neurological Disease
Learn More
January 18, 2021
Neurogene and University of Edinburgh Announce Research Collaboration to Advance Next Generation Gene Therapies
Learn More
December 15, 2020
Neurogene Closes $115 Million Series B Financing
Learn More
December 2, 2020
Neurogene Announces EMA Grants Orphan Drug Designation for Aspartylglucosaminuria Gene Therapy
Learn More
November 12, 2020
Neurogene Announces First Patient Enrolled in Natural History Study Evaluating Two Subtypes of Batten Disease
Learn More
September 16, 2020
Neurogene Appoints Industry Veteran Robert A. Baffi, Ph.D. to Board of Directors
Learn More
August 11, 2020
Neurogene Announces FDA Orphan Drug Designation for CLN7 Batten Disease Gene Therapy
Learn More
July 14, 2020
Neurogene Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President of Clinical Development
Learn More
July 5, 2020
FDA Grants Orphan Drug Designation to Neurogene’s Gene Therapy for the Treatment of CLN5 Batten Disease
Learn More
February 10, 2020
Neurogene Joins Behind the Seizure® Program, Sponsors Genetic Testing for Children with Seizures
Learn More
September 24, 2019
Neurogene Appoints Christine Mikail as President
Learn More
July 25, 2019
Neurogene Offers Access to Genetic Testing to Patients Suspected of Having a Lysosomal Storage Disease
Learn More
July 18, 2019
Neurogene Initiates Natural History Study of Charcot-Marie Tooth Disease (CMT4J)
Learn More
February 27, 2019
Neurogene Appoints Industry Leaders Dr. Sukumar Nagendran and Dr. Serge Stankovic to Board of Directors
Learn More
February 12, 2019
Neurogene Raises $68.5 Million in Series A Financing to Advance Multiple Programs in Devastating Neurological Diseases
Learn More
February 7, 2019
Neurogene Announces Presentation of Preclinical Data for Gene Therapies to Treat AGU and CMT4J, Two Rare and Devastating Neurodegenerative Disorders
Learn More
January 23, 2019
Neurogene Appoints Stuart Cobb, Ph.D. as Chief Scientific Officer
Learn More